Which is performing better right now, ABBV or MRK?

Over the past month ABBV is +8.7% and MRK is +0.7%, so ABBV is ahead on that window. Year to date the figures are +24.9% for ABBV and +38.7% for MRK.

What are the key levels for ABBV and MRK?

ABBV: resistance $300.00, support $275.00; MRK: resistance $150.00, support $145.12. Levels come from recent swing zones and round numbers, recomputed daily.

When do ABBV and MRK report next?

ABBV: 2026-10-30. MRK: 2026-10-29. Earnings reset both the trend and the levels above, so a comparison made today is only good until the next report.

What does the ABBV/MRK ratio mean?

It is simply ABBV's price divided by MRK's — 1.9556 today. When the ratio rises, ABBV is outperforming; when it falls, MRK is. Comparing it to its own 50- and 200-day averages shows whether the current leadership is new or long-standing.

ABBV vs MRK

AbbVie Inc. against Merck & Co. — live side-by-side technical comparison.

Prices as of 2026-10-16T20:00:03+00:00 UTC · updates daily

Who leads right now

ABBV leads 4 of the 5 windows we measure — over 1 month ABBV is +8.7% and MRK +0.7%; over year to date ABBV is +24.9% and MRK +38.7%. The ABBV/MRK price ratio stands at 1.9556, above its 50-day average of 1.8108, and above the 200-day average of 1.878. A ratio above its own average means ABBV is gaining on MRK; on this reading the recent edge belongs to ABBV.

Performance side by side

	ABBV	MRK
Price	$285.42	$145.95
1 day	+0.7%lead	+0.5%
5 days	+3.2%lead	+0.2%
1 month	+8.7%lead	+0.7%
6 months	+36.6%lead	+26.4%
Year to date	+24.9%	+38.7%lead
52-week position	94% of range	85% of range
52-week range	$190.75–$291.40	$82.01–$156.92
vs 50-day average	above $262.45	above $145.12
vs 200-day average	above $233.95	above $124.87
RSI (14)	71	45
Next earnings	2026-10-30	2026-10-29

Where each one stands

ABBV — AbbVie Inc.

ABBV trades at $285.42, above its 50-day average of $262.45, and above the 200-day at $233.95. It sits at 94% of its 52-week range ($190.75–$291.40); 14-day RSI is 71, in overbought territory; an average session moves it about 2.4%. For levels, the first level overhead is $300.00 (5.1% away) and the first support below is $275.00 (3.6% down). On the checklist the page runs for every asset, 6 of 6 checks read bullish — the lean is bullish.

MRK — Merck & Co.

MRK trades at $145.95, above its 50-day average of $145.12, and above the 200-day at $124.87. It sits at 85% of its 52-week range ($82.01–$156.92); 14-day RSI is 45, in neutral territory; an average session moves it about 2.7%. For levels, the first level overhead is $150.00 (2.8% away) and the first support below is $145.12 (0.6% down). On the checklist the page runs for every asset, 4 of 6 checks read bullish — the lean is bullish.

Which one moves harder

MRK is the more volatile of the two — an average session moves it 2.7% against 2.4% for ABBV, so an identical position size carries roughly 1.1× the daily risk.

What would change the picture

The comparison turns on those levels: ABBV clearing $300.00 or losing $275.00; MRK clearing $150.00 or losing $145.12. Until one of them gives way, the relative reading above stands.

Questions people ask about ABBV vs MRK

Which is performing better right now, ABBV or MRK?: Over the past month ABBV is +8.7% and MRK is +0.7%, so ABBV is ahead on that window. Year to date the figures are +24.9% for ABBV and +38.7% for MRK.
Is ABBV or MRK more volatile?: MRK is the more volatile of the two — an average session moves it 2.7% against 2.4% for ABBV, so an identical position size carries roughly 1.1× the daily risk.
What are the key levels for ABBV and MRK?: ABBV: resistance $300.00, support $275.00; MRK: resistance $150.00, support $145.12. Levels come from recent swing zones and round numbers, recomputed daily.
When do ABBV and MRK report next?: ABBV: 2026-10-30. MRK: 2026-10-29. Earnings reset both the trend and the levels above, so a comparison made today is only good until the next report.
What does the ABBV/MRK ratio mean?: It is simply ABBV's price divided by MRK's — 1.9556 today. When the ratio rises, ABBV is outperforming; when it falls, MRK is. Comparing it to its own 50- and 200-day averages shows whether the current leadership is new or long-standing.